Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly

Revenues up 8% in the quarter driven by newer products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly

4Q Revenues: $6.1 billion (+8%)

4Q Earnings: $1.5 billion (+33%)

FY Revenues: $22.3 billion (+4%)

FY Earnings: $8.3 billion (up from $3.2 billion FY18)

Comments: Key growth products launched since 2014, including Trulicity, Taltz, Jardiance, Verzenio, Olumiant, Emgality, Basaglar, and Cyramza, represented approximately 46% of total revenue.  Revenue in the U.S. increased 7% to $3.5 billion. Revenue outside the U.S. increased 10% to $2.6 billion. Trulicity sales were $1.2 billion in the quarter, up 31%. Talz sales were up 37% to $420 million. Jardiance sales were $268 million, up 39%. Verzenio sales were $179 million, up from $83 million 4Q18. Cyramza sales were up 11% to $245 million. Humalog sales were down 1% to $763 million. Alimta sales were down 5% to $530.7 million. Forteo sales were down 18% to $360.2 million and Cialis sales were down 44% to $197.8 million. The increase in earnings was primarily driven by higher operating income, partially offset by higher income taxes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics